|
Video: What is a Stock Split?
|
|
ALX Oncology Holdings is a holding company. Through its subsidiaries, Co. is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on capabilities in protein engineering and oncology led by the CD47 blocker, evorpacept. Co.'s primary product candidate, evorpacept, is a CD47 blocking biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction and breast cancer. According to our ALX Oncology Holdings stock split history records, ALX Oncology Holdings has had 0 splits. | |
|
ALX Oncology Holdings (ALXO) has 0 splits in our ALX Oncology Holdings stock split history database.
Looking at the ALX Oncology Holdings stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into ALX Oncology Holdings shares, starting with a $10,000 purchase of ALXO, presented on a split-history-adjusted basis factoring in the complete ALX Oncology Holdings stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
07/20/2020 |
|
End date: |
04/18/2024 |
|
Start price/share: |
$30.33 |
|
End price/share: |
$15.74 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-48.10% |
|
Average Annual Total Return: |
-16.06% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$5,188.48 |
|
Years: |
3.75 |
|
|
|
|
|